{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T02:02:54Z","timestamp":1766023374980,"version":"3.48.0"},"reference-count":13,"publisher":"e-Century Publishing Corporation","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Transl Res"],"DOI":"10.62347\/rghc1274","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T03:15:45Z","timestamp":1730344545000},"page":"5978-5980","source":"Crossref","is-referenced-by-count":0,"title":["Suspected agomelatine-induced tongue temperature perception abnormality: a case report"],"prefix":"10.62347","volume":"16","author":[{"given":"Li-Lei","family":"Lei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"48694","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","unstructured":"Hong W, Si TM, Li LJ, Xu XF, Gao CG, Li KQ, Shi JF, Jiao ZA, Peng DH, Li Y, Yao ZJ, Qiu CJ, Wang HL, Wang YM, Huang JZ and Fang YR. Argonaut melanesia treatment depression clinical expert advice. Clinical application recommendation on agomelatine in treatment of major depressive disorder. Chinese J New Drugs 2018; 37: 601-606."},{"key":"ref1","doi-asserted-by":"publisher","first-page":"734","DOI":"10.3390\/brainsci13050734","article-title":"Agomelatine: a potential multitarget compound for neurodevelopmental disorders","volume":"13","author":"Savino","year":"2023","unstructured":"Savino R, Polito AN, Marsala G, Ventriglio A, Di Salvatore M, De Stefano MI, Valenzano A, Marinaccio L, Bellomo A, Cibelli G, Monda M, Monda V, Messina A, Polito R, Carotenuto M and Messina G. Agomelatine: a potential multitarget compound for neurodevelopmental disorders. Brain Sci 2023; 13: 734.","journal-title":"Brain Sci"},{"key":"ref2","unstructured":"Li LJ and Ma X. Chinese guidelines for the prevention and treatment of depression disorder (second edition). China Medical Electronic Audio-Visual Publishing House (Beijing) 2015."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1177\/0706743716659061","article-title":"Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: introduction and methods","volume":"61","author":"RW","year":"2016","unstructured":"Lam RW, Kennedy SH, Parikh SV, MacQueen GM, Milev RV and Ravindran AV; CANMAT Depression Work Group. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: introduction and methods. Can J Psychiatry 2016; 61: 506-509.","journal-title":"Can J Psychiatry"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1017\/S1461145710001045","article-title":"The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors","volume":"14","author":"Millan","year":"2011","unstructured":"Millan MJ, Marin P, Kamal M, Jockers R, Chanrion B, Labasque M, Bockaert J and Mannoury la Cour C. The melatonergic agonist and clinically active antidepressant, agomelatine, is a neutral antagonist at 5-HT(2C) receptors. Int J Neuropsychopharmacol 2011; 14: 768-783.","journal-title":"Int J Neuropsychopharmacol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S0140-6736(11)60095-0","article-title":"Novel melatonin-based therapies: potential advances in the treatment of major depression","volume":"378","author":"Hickie","year":"2011","unstructured":"Hickie IB and Rogers NL. Novel melatonin-based therapies: potential advances in the treatment of major depression. Lancet 2011; 378: 621-631.","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/JCP.0000000000000878","article-title":"Efficacy and safety of agomelatine vs paroxetine hydrochloride in Chinese Han patients with major depressive disorder: a multicentre, double-blind, noninferiority, randomized controlled trial","volume":"38","author":"YM","year":"2018","unstructured":"Yu YM, Gao KR, Yu H, Shen YF and Li HF. Efficacy and safety of agomelatine vs paroxetine hydrochloride in Chinese Han patients with major depressive disorder: a multicentre, double-blind, noninferiority, randomized controlled trial. J Clin Psychopharmacol 2018; 38: 226-233.","journal-title":"J Clin Psychopharmacol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12991-023-00473-y","article-title":"A multicenter, randomized controlled study on the efficacy of agomelatine in ameliorating anhedonia, reduced motivation, and circadian rhythm disruptions in patients with major depressive disorder (MDD)","volume":"22","author":"Guo","year":"2023","unstructured":"Guo P, Xu Y, Lv L, Feng M, Fang Y, Huang WQ, Cheng SF, Qian MC, Yang S, Wang SK and Chen HX. A multicenter, randomized controlled study on the efficacy of agomelatine in ameliorating anhedonia, reduced motivation, and circadian rhythm disruptions in patients with major depressive disorder (MDD). Ann Gen Psychiatry 2023; 22: 46.","journal-title":"Ann Gen Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2165\/11593960-000000000-00000","article-title":"A benefit-risk assessment of agomelatine in the treatment of major depression","volume":"34","author":"Howland","year":"2011","unstructured":"Howland RH. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf 2011; 34: 709-731.","journal-title":"Drug Saf"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Demyttenaere K. Agomelatine: a narrative review. Eur Neuropsychopharmacol 2011; 21 Suppl 4: S703-S709.","DOI":"10.1016\/j.euroneuro.2011.07.004"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2165\/00023210-200620120-00003","article-title":"Agomelatine: a preliminary review of a new antidepressant","volume":"20","author":"Zupancic","year":"2006","unstructured":"Zupancic M and Guilleminault C. Agomelatine: a preliminary review of a new antidepressant. CNS Drugs 2006; 20: 981-992.","journal-title":"CNS Drugs"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1517\/14656566.2014.862233","article-title":"The mechanism, efficacy, and tolerability profile of agomelatine","volume":"15","author":"MacIsaac","year":"2014","unstructured":"MacIsaac SE, Carvalho AF, Cha DS, Mansur RB and McIntyre RS. The mechanism, efficacy, and tolerability profile of agomelatine. Expert Opin Pharmacother 2014; 15: 259-274.","journal-title":"Expert Opin Pharmacother"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Baldaçara L. Duloxetine: an update. Research, Society and Development 2024; 13: e7313345331.","DOI":"10.33448\/rsd-v13i3.45331"}],"container-title":["American Journal of Translational Research"],"original-title":[],"link":[{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/10\/ajtr0158099.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T01:57:58Z","timestamp":1766023078000},"score":1,"resource":{"primary":{"URL":"https:\/\/e-century.us\/files\/ajtr\/16\/10\/ajtr0158099.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":13,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.62347\/rghc1274","relation":{},"ISSN":["1943-8141"],"issn-type":[{"type":"electronic","value":"1943-8141"}],"subject":[],"published":{"date-parts":[[2024]]}}}